Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics


Crinetics Pharmaceuticals, Inc. (CRNX): $17.30

0.12 (+0.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CRNX Stock Summary

  • Crinetics Pharmaceuticals Inc's stock had its IPO on July 18, 2018, making it an older stock than merely 7.18% of US equities in our set.
  • CRNX's price/sales ratio is 7,992.06; that's higher than the P/S ratio of 99.68% of US stocks.
  • As for revenue growth, note that CRNX's revenue has grown -94.05% over the past 12 months; that beats the revenue growth of merely 1.03% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Crinetics Pharmaceuticals Inc, a group of peers worth examining would be ATOM, ETON, ARNA, CRSP, and VNRX.
  • Visit CRNX's SEC page to see the company's official filings. To visit the company's web site, go to www.crinetics.com.

CRNX Stock Price Chart Interactive Chart >

Price chart for CRNX

CRNX Price/Volume Stats

Current price $17.30 52-week high $23.70
Prev. close $17.18 52-week low $11.61
Day low $17.02 Volume 150,260
Day high $18.11 Avg. volume 142,793
50-day MA $16.18 Dividend yield N/A
200-day MA $14.98 Market Cap 571.40M

Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio


Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.


CRNX Latest News Stream


Event/Time News Detail
Loading, please wait...

CRNX Latest Social Stream


Loading social stream, please wait...

View Full CRNX Social Stream

Latest CRNX News From Around the Web

Below are the latest news stories about Crinetics Pharmaceuticals Inc that investors may wish to consider to help them evaluate CRNX as an investment opportunity.

Crinetics Pharmaceuticals Stock Is Showing Strong Insider Interest

Clinical-stage pharmaceutical company Crinetics Pharmaceuticals Inc. (CRNX) has seen a key corporate insider snap up shares recently. Regulations require corporate insiders to make their trading activity public, and their actions could signal to investors that now is the time to get in on the action. In the last 12 days, corporate insider Perceptive Advisors LLC, which owns a more than 10% stake in the company, has bought $5 million worth of Crinetics shares. (See Crinetics stock analysis on TipRanks) On March 31, H. C. Wainwright analyst Douglas Tsao reiterated a Buy rating on the stock with a $30 price target (81.3% upside potential).

Kailas Salunkhe on TipRanks | April 21, 2021

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $75.0 million. Investors in the offering included Deep Track Capital, Bain Capital Life Sciences, and Driehaus Capital Management, with participation from other new and existing stockhol...

Yahoo | April 12, 2021

What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?

A look at the shareholders of Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) can tell us which group is most powerful...

Yahoo | April 12, 2021

Crinetics Pharma raises $75M via equity offering

Crinetics Pharmaceuticals (CRNX) has priced its public offering of ~4.6M common shares at $16.44/share, for expected gross proceeds of ~$75M. Net proceeds will be used to fund the development of paltusotine and other R&D programs, for working capital and general corporate purposes. SVB Leerink is acting as sole bookrunning manager.Closing...

Seeking Alpha | April 8, 2021

Crinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Crinetics Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call....

SA Transcripts on Seeking Alpha | March 31, 2021

Read More 'CRNX' Stories Here

CRNX Price Returns

1-mo 6.53%
3-mo 13.67%
6-mo 24.10%
1-year -6.59%
3-year N/A
5-year N/A
YTD 22.61%
2020 -43.76%
2019 -16.34%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.1088 seconds.